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Abstract
The implantation process involves complex and synchronized molecular and cellular events
between the uterus and the implanting embryo. These events are regulated by paracrine and
autocrine factors. Trophoblast invasion and migration through the uterine wall is mediated by
molecular and cellular interactions, controlled by the trophoblast and the maternal
microenvironment. This review is focused on the molecular constituents of the human trophoblast,
their actions and interactions, including interrelations with the uterine endometrium.
1. Introduction
Successful implantation depends on synchronization
between the developmental stages of the embryo itself
and the complex series of molecular and cellular events
that are induced in the pregnant uterus by paracrine and
autocrine regulators [1]. Embryos prepare for implanta-
tion during their cleavage stage. Successive cleavages must
produce sufficient cells by the time the blastocyst is
formed to permit the full formation of inner cell mass and
trophectodermal cells. The latter are the origin of the
cytotrophoblastic cells which ensue to become either the
villous cytotrophoblastic cells which will proliferate and
differentiate by fusion to form the syncytiotrophoblast, or
they will stream out of the syncytiotrophoblast to form
mononuclear multilayered invasive extravillous cytotro-
phoblastic cells [2]. The process of implantation begins
six to seven days following fertilization [3] and consists
basically of three stages [4]. Apposition is the first stage
denoting the initial, still unstable, adhesion of the blasto-
cyst to the uterine wall. At this stage the pinopodes, which
are micro protrusions from the apical uterine epithelium
surface, inter-digitate with microvilli on the apical syncy-
tiotrophoblast surface of the blastocyst[5] (Figure 1). The
stable adhesion, which is the next step, reveals an
increased physical contact between the blastocyst and the
uterine epithelium, while the embryonic pole is oriented
toward the epithelium. The last stage is the invasion proc-
ess, which starts with the penetration of the syncytiotro-
phoblasts through the uterine epithelium and followed by
infiltration of the mononuclear cytotrophoblasts invad-
ing the entire endometrium, the inner third of the myo-
metrium and the uterine vasculature. Villous
cytotrophoblast cells at the tip of the anchoring villi pro-
liferate outwards from the underlying basement mem-
brane to form cell columns from which cells migrate into
the decidua (interstitial trophoblast cells) and invade the
maternal spiral arteries and designate the endovascular
trophoblast cells. The latter allows the trophoblasts to be
in direct contact with the maternal blood establishing the
uteroplacental circulation [4]. Trophoblast invasion and
migration is probably controlled by components of the
trophoblast itself and maternal microenvironment,
through molecular and cellular interaction (Figure 2).
The human implantation process is unique thus no other
mammals can provide a true model [2]. Ethical restric-
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tions and limited availability of human placental tissue
limits the possibilities of human implantation studies.
Consequently most knowledge comes from in vitro exper-
iments using cultured human trophoblasts or cell-lines,
mainly obtained from choriocarcinoma. Although the dif-
ferences in reproductive physiology between species limit
the relevance, knowledge on the possible role of various
factors in the implantation process comes from knockout-
studies in mice. Primates provide a more physiological
relevant model, therefore in vivo and in vitro studies in
baboons have contributed to our knowledge [6]. All in all,
human in vitro and mammal in vitro and in vivo studies
have provided important information, which helped in
understand at least part from the complex process of
implantation. This review focuses on the molecular con-
stituents of the human trophoblast, their actions and
interactions, which seem to be crucial for successful
implantation.
2. Cell adhesion molecules
2.1 Integrins
During the mid-luteal stage of the menstrual cycle, appar-
ently in response to progesterone, epithelial apical mem-
brane projections named pinopodes appear in the uterus
[5]. The biological nature of the pinopodes has not been
determined, but their short appearance during the
implantation window, interconnecting with microvilli on
the apical syncytiotrophoblast surface of the blastocyst,
suggests an involvement in embryo implantation [7].
Adherence of the trophectoderm cells of the blastocyst to
the pinopode membrane has been suggested to occur
through adhesive molecules such as E-cadherin, present in
the pinopode epithelial membrane [5]. In vitro studies
showed that although no direct contact between trophec-
toderm and pinopode is seen, blastocysts tends to attach
to areas of cultured endometrial epithelium containing
pinopodes [5].
Integrins are heterodimeric membrane glycoproteins,
composed of α and β subunits, capable of binding to var-
ious extracellular matrix (ECM) components and cell
adhesion molecules, thereby influencing and mediating
adhesion, migration, invasion, cytoskeleton reorganiza-
tion and cellular signaling [8]. Endometrial integrins are
hormone-dependent and vary throughout the menstrual
cycle [9]. The integrin repertoire of the endometrium may
play an important role for obtaining a successful implan-
tation. According to a timed expression correlating with
embryo attachment, the αVβ3 and the α4β1 integrins are
considered markers of uterine receptivity [10-12]. αVβ3
has been shown to be highly expressed at the time of
embryo attachment, and aberrant expression of αVβ3 is
associated with infertility [13,14]. Women with recurrent
miscarriages were found to have a lower concentration of
α4β1 and α5β1 integrins in the stroma during the implan-
tation window, than women with unexplained infertility
[15]. The relevance of integrins alteration, in glandular
epithelium or stroma, but not in luminal epithelium is
not well understood, since they are not likely to be
involved in the early parts of implantation [16]. The tro-
phectoderm also express several integrins, α3, α5, β1, β3,
β4 and β5, supposed to be implicated in blastocyst attach-
ment to the endothelial surface [17-19]. Trophoblasts
modulate their integrin repertoire during invasion of the
stroma and during differentiation, varying in invasive and
non-invasive cells [2,16]. Several factors known to be
involved in the implantation process may act through
mediation of integrins. For example, Insulin-like growth
factor (IGF)-I-induced migration of extravillous trophob-
last cells (EVT) probably involves internalization of the
α5β1-integrin on EVT [19], as well as influencing the
αVβ3-integrin pathway [18]. In female mice lacking a
functional integrin β1 gene, embryos develop normally to
the blastocyst stage but fail to implant properly and die
[20]. No other integrins were found in knockout studies
to be involved in implantation defects [21], but inactiva-
tion of αVβ3 by the disintegrin echistatin significantly
reduced implantation sites in mice [22]. Apparently sev-
eral integrins may have a redundant role in implantation
[23].
2.2 MUC1
Uterine cell-surface glycoproteins such as MUC1 are
thought to provide a barrier to trophoblast invasiveness,
by controlling accessibility of integrin receptors to their
ligands [8]. MUC1 increases from the proliferative to the
secretory phase in endometrial tissue and then decreases
in the late secretory phase [24]. Progesterone combined
with estrogen up-regulates MUC1 at the receptive
endometrium [24]. Blastocysts were shown to deplete
MUC1 locally from the implantation site, whereas during
the apposition phase, when the blastocyst apparently
must be stationary in position, MUC1 was up-regulated
[25]. MUC1 may thereby serve as an anti-adhesive mole-
cule that hinders blastocyst attachment to the uterine epi-
thelium until 3 days after entrance to the uterus [26].
3. Extracellular matrix proteins
The trophoblastic cells are confronted with various matrix
proteins and basement membranes, when penetrating the
uterine wall. These ECM components, including collagens
(Col), fibronectin (FN), laminin (LN), vitronectin (VN),
trophin and tastin, influence cell functions by binding to
integrins, thereby effecting adhesion, migration, differen-
tiation and spreading [2]. Trophin and Tastin for example
can be found in endometrial epithelium as well as in tro-
phoblasts, and may be involved in blastocyst attachment
by forming a cell-adhesion molecular complex [26].Reproductive Biology and Endocrinology 2005, 3:56 http://www.rbej.com/content/3/1/56
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The components of the ECM are changed during the men-
strual cycle [27]. The changes associated with decidualiza-
tion, during the mid-secretory phase, are especially
relevant for implantation. This includes an increase in
hyaluronan, a decrease in collagen VI and a slower pro-
duction of collagen III and I. During decidualization, stro-
mal fibroblasts differentiate into decidual cells, and a
basement membrane, containing laminin, entactin, colla-
gen IV and heparan sulphate proteoglycan, appears
around each cell [28].
ECM components affect the behavior and function of tro-
phoblastic cells by affecting matrix metalloproteases
(MMPs) and their tissue inhibitors (TIMPs) as shown by
Xu et al, 2001 [29]. Trophoblasts, grown in the presence
of VN, LN or FN, secreted more MMP-9 than in the pres-
ence of Col I, or IV, whereas MMP-2, TIMP-2 and MMP-14
were not affected. TIMP-3 on the contrary was inhibited
by the presence of VN. Trophoblast adhesiveness was
highest in the presence of Col I and IV compared with the
other matrix proteins. Since cytotrophoblast cells also
produce LN, FN and VN during the first trimester, these
matrix proteins may be part of an autocrine mechanism,
regulating MMP expression and cell invasiveness [29].
4. Growth factors
4.1 Epidermal Growth Factor
Epidermal Growth Factor (EGF) is expressed both in
decidual and trophoblastic cells [30] and affects implan-
tation in several ways. EGF induces trophoblast invasion
[31,32], trophoblast differentiation [33,34] and trophob-
last proliferation [35], and is therefore regarded a major
regulator of the implantation process. EGF has been
shown to increase MMP-2 and MMP-9 activity in trophob-
lastic cells [32,36,37], and also urokinase-type plasmino-
gen activator (uPA) and plasminogen activator inhibitor-
1 (PAI-1) activity [36] in trophoblastic cells, thereby
inducing cell invasion. EGF stimulates secretion of human
chorionic gonadotrophin (hCG) and human placental
lactogen (hPL) from trophoblastic cells [38,33], and has
been shown to induce α2 integrin expression in a chorio-
carcinoma cell-line, an effect found to be related to
increased invasiveness [38].
4.2 Heparin-binding EGF-like growth factor
Heparin-binding EGF-like growth factor (HB-EGF) shares
a common receptor with EGF and transforming growth
factor (TGF)-α. HB-EGF is expressed in stromal and epi-
thelial cells of the uterus and is thought to regulate
endometrial proliferation, secretion and decidualization
[21]. The expression of HB-EGF is maximal in the mid-
secretory phase in uterine epithelial cells; therefore HB-
EGF may also be involved in the regulation of blastocyst
implantation [21].
4.3 Transforming growth factor β
TGF-β is expressed both in endometrial and trophoblastic
cells [2]. TGF-β was shown to inhibit trophoblast prolifer-
ation and invasion apparently by stimulating TIMP secre-
tion and decreasing MMP activation through down-
regulation of plasminogen activators [39]. In another
study TGF-β was found to inhibit trophoblast invasion by
reducing MMP-9 and uPA secretion, but did not affect
TIMP levels or cell proliferation [40]. Elevated TGF-β
activity has been reported in the plasma of pre-eclamptic
mothers [41] and may be implicated in the impaired
implantation associated with pre-eclampsia [42].
4.4 Insulin-like growth factor binding protein-1
Insulin-like growth factor binding protein-1 (IGFBP-1) is
the main secretory product of the decidualized
endometrium. IGFBP-1 modulates the metabolic effect of
insulin-growth factor (IGF)-I and IGF-II and has been
shown to increase the gelatinolytic activity of trophop-
blasts [43] and trophoblast invasiveness mainly by
increasing cell migration [44,45].
5. Cytokines
5.1 Leukaemia inhibitory factor
Leukaemia inhibitory factor (LIF) secreted from the uterus
is regarded an important factor in embryo implantation.
Female mice lacking a functional LIF gene are fertile, but
their blastocysts fail to implant, even though they are via-
ble and can implant when transferred to wild-type recipi-
ents [46]. Maximal expression of LIF in endometrial
epithelium is during the implantation window [21]. LIF
and its receptor are also expressed in pre-implantation
embryos [47] and in cytotrophoblasts [48]. LIF inhibits
gelatinase activity in cytotrophoblasts, thereby effecting
cell invasiveness [49]. LIF may also be involved in
immune tolerance through regulation of HLA-G, a class I
MHC molecule specifically expressed by invasive cytotro-
phoblast cells [50].
5.2 Interleukin-1
Interleukin-1 (IL-1) is present at the feto-maternal inter-
phase; trophoblastic cells and decidualized stromal cells
produce IL-1, and the IL-1 receptor is present in endome-
trial epithelial cells as well as in trophoblasts [2]. IL-1 may
be one of the first signals of the blastocyst acting upon the
endometrium, since in vitro IL-1 increases endometrial
secretion of prostaglandin E2, LIF and of integrin β3 subu-
nit expression [51]. In mice IL-1 receptor antagonist given
prior to implantation significantly reduces the number of
implanted embryos, indicating a role for IL-1 in embryo
implantation [52]. IL-1 can stimulate MMP-9 activity in
trophoblasts [53] and expression in endometrial stroma
cells [54], thereby inducing trophoblast invasion Among
other cytokines also present at the maternal-feto interface
are IL-6, which stimulates MMP-2 and MMP-9 activityReproductive Biology and Endocrinology 2005, 3:56 http://www.rbej.com/content/3/1/56
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[55] whereas IL-10 down-regulates MMP-9 and trophob-
last invasion [56].
6. Hormones
6.1 Human Chorionic Gonadotropin
Syncytiotrophoblastic cells secrete hormones including
progesterone and human chorionic gonadotropin (hCG),
which play important roles in the implantation process.
hCG affects several processes during pregnancy, besides
the well-known maintenance of the corpus luteum,
including cell growth and differentiation. The trophob-
lasts themselves express a truncated and inactive hCG
receptor until ninth week of gestation, then switching to
the full length receptor, allowing hCG autocrinic regula-
tion of various functions including cell differentiation in
the trophoblasts [57]. In trophoblastic neoplasms these
receptors have been found to be over-expressed [2]. Posi-
tive correlation between hCG level and trophoblast inva-
sion has been shown in ectopic pregnancies [58,59],
indicating a possible stimulatory effect on trophoblast
invasiveness. hCG was found in vitro to increase invasive-
ness of a trophoblastic choriocarcinoma cell-line [60]
however in vitro studies of primary trophoblast showed
the opposite effect [61,62]. Therefore, the influence of
hCG on trophoblast in vivo invasion remains unclear.
hCG stimulates the cAMP pathway, and forskolin, which
directly activates adenylate cyclase and increases cAMP,
also stimulates trophoblast invasiveness, both in a tro-
phoblast choriocarcinoma cell-line and in primary tro-
phoblastic cells [32]. This is in agreement with the finding
that hCG increases MMP-9, an important key-factor in
trophoblast invasion [57]. Lately hCG was shown in vitro
to stimulate trophoblast migration through an IGF-II
effect [63].
hCG influences several uterine factors, for example
increases the expression of COX-2 gene, an enzyme
involved in prostaglandin biosynthesis [21], LIF and vas-
cular endothelial growth factor (VEGF) [57], suggesting a
role in endometrial vascularization. In the baboon hCG
was shown to cause physiological effects on the uterine
endometrium in vivo, including an increase in glycodelin
expression and secretion by the glandular epithelium, and
differentiation of subepithelial stromal fibroblasts charac-
terized by expression of the alpha smooth muscle actin,
associated with the initiation of decidualization [64,65].
This suggests that the primate blastocyst signal modulates
the uterine environment prior to implantation [64].
Hyperglycosylated hCG (HhCG), also called invasive tro-
phoblast antigen (ITA), is an hCG variant with extra-large
O-linked oligosaccharides. HhCG is the predominant
form of hCG in early pregnancy and in choriocarcinoma,
where aggressive trophoblast invasion takes place [66]. It
is produced by poorly differentiated or invasive trophob-
last cells and decreases as pregnancy advances [67]. The
fact that HhCG is dominant around the time of implanta-
tion and in the 3 weeks that follow [68] makes it an inter-
esting molecule that deserves further exploration. Low
maternal mid-trimester urine HhCG has been found to
predict preeclampsia, which is associated with poor tro-
phoblast invasion [69].
6.2 Progesterone
Progesterone has a crucial role in preparing the uterus for
the developing embryo and for obtaining a successful
pregnancy. Stromal cells differentiate into decidual cells
in respond to progesterone during the decidualization
process, characterized by morphological changes and
secretion of prolactin [70]. Progesterone is also required
for maintenance of the pregnancy by stimulating and
maintaining uterine functions, necessary for early embry-
onic development, implantation, placentation and fetal
development. Hormones such as hCG, produced by the
trophoblast, maintain this progesterone production in
early pregnancy [71]. Progesterone was suggested to affect
trophoblast invasiveness through the down-regulation of
MMP-9 [72]. Progesterone is known to restrain endome-
trial breakdown by inhibiting MMPs. This inhibitory
effect implies that progesterone impedes the invasion of
trophoblast cells into the endometrial tissue. In a recent
report progesterone was found to decrease invasion and
gelatinase expression in early first trimester trophoblast
cells and to increase cell invasion and MMP-2 expression
in late trophoblast cells [73]. A differential progesterone
receptor (PR) profile was documented with the domi-
nance of PRB in the early trophoblast and dominance of
PRA in the late trophoblast [73]. This differential PR pro-
file is compatible with the inverse temporal effect of the
hormone on the trophoblast cells. In mice a similar dual
role of progesterone in embryo implantation has been
reported, when progesterone promoted attachment and
invasion of primary trophoblasts, mainly through MMP-2
stimulation, but inhibited invasion of secondary trophob-
lasts [74].
7. Inflammatory factors
7.1 Cortico-releasing hormone
The implanting embryo suppresses the maternal immune
process, thereby preventing rejection. Cortico-releasing
hormone (CRH) is produced by both trophoblasts and
placental deciduas [75]. In mice, implantation can be
highly reduced by anti-CRH antibody, indicating a role in
embryo implantation [76]. Fas and its ligand FasL,
belongs to the tumor necrosis family (TNF). Fas and Fas-
FasL interaction, plays an important role in the regulation
of immune tolerance, mainly by inducing apoptosis in
cells carrying Fas, including T and B lymphocytes [75].
FasL is expressed on cytotrophoblastc as well as on mater-
nal decidual cells of the placenta [77]. CRH was found inReproductive Biology and Endocrinology 2005, 3:56 http://www.rbej.com/content/3/1/56
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vitro to stimulate FasL expression in extravillous human
trophoblasts, thereby enabling them to induce apoptosis
of the surrounding activated T lymphocytes [75]. Rats
treated with a CRH receptor 1 (CRHR1) antagonist had
diminished FasL endometrial expression and reduced
number of implantation sites, suggesting that locally pro-
duced CRH promotes implantation and maintenance of
early pregnancy mainly by killing activated T cells [75].
The CRH-Fas-FasL system is not the sole maternal immu-
netolerance mechanism preventing embryo rejection.
Mice with an inactivating mutation of Fasl gene or CRH
and CRHR1-deficient mice [78-80] can be fertile.
7.2 Tumor necrosis factor-α
The pleiotropic cytokine TNF-α and its two receptors are
present in the endometrium, as well as in placental tro-
phoblasts [81]. TNF-α was shown in vitro to increase uPA
secretion from cytotrophoblasts, thereby properly
enhances the degradation of fibronectin during trophob-
last penetration of the endometrial ECM [84]. Although,
TNF-α did not affect MMP-9 concentration, the up-regula-
tion of uPA increases activation of MMP-9 through the
plasminogen activation system, thereby enhancing tro-
phoblast invasiveness [84]. This is consistent with another
report describing TNF-α stimulation of MMP-9 gelatino-
lytic activity, without affecting MMP-9 concentration [53].
At the same time, TNF-α decreases MMP-2 concentration
and activity as well as hCG secretion [53,84]. It is there-
fore suggested, that high TNF-α levels presented during
inflammatory responses [85], could be responsible in
pathologic processes such as pregnancy loss, preterm
delivery and preeclampsia, for abnormal trophoblast
endocrine function [84,86]. In a recent study, despite
increased MMP-9 expression, TNF-α was found to inhibit
in vitro trophoblast migration and invasion. However, the
plasminogen activator inhibitor-1 (PAI-1) that blocks the
plasminogen activator system, was found to be increased
[86]. Thus, TNF-α seems to exert diverse in vitro effects,
depending on individual trophoblast preparation, type of
cell-line and cytokine concentration. This affects the value
of conclusions which can be derived from in vitro studies.
A link between elevated PAI-1 levels detected in plasma
and syncytium of preeclamptic women, and elevated TNF-
α found in preeclamptic sera, villi and deciduas has been
suggested [86]. The elevated TNF-α level could result from
local hypoxic conditions developing under reduced
maternal and fetal vascular perfusion [87].
7.3 Prostaglandins
Prostaglandins are synthesized from arachidonic acid by
phospholipase A2, followed by cyclooxygenase (COX).
Prostaglandin E2  (PGE2) is essential for mammalian
female reproduction. PGE2 is involved in regulation of
decidualization of endometrial stomal cells [88], appar-
ently through stimulation of IL-11, since blocking of IL-11
in PGE2 treated cells reduces decidualization and COX
inhibitor reduces IL-11 secretion from these cells [89]. In
rats, expression of the PGE receptor EP2 is highly detected
at implantation sites in luminal epithelium, peaking on
day 6 of pregnancy [90]. Phospholipase A2 and PGE2
receptor were described to be up-regulated in human
endometrium during the window of implantation [91].
Experiments in mice have shown that prostaglandins are
essential for the correct timing of implantation [92].
Reduced levels of COX-2 or COX-2 ligands cause deferred
implantation and reduced litter size, and prostaglandin
treatment resumes on-time implantation [92]. COX-1,
COX-2 and prostaglandin E synthase (PGES), which catal-
yses COX products to PGE2, are highly expressed in mice
at the blastocyst stage [93].
8. Extracellular degrading matrix proteinases
8.1 MMPs
The matrix metalloproteinases (MMPs) are a family of
zinc-containing endopeptidases capable of degrading all
components of the ECM, both interstitial matrix and base-
ment membrane. MMPs are thought to play an important
role in tumor progression and metastasis [94]. Twenty-six
mammalian and twenty-two human MMPs are known so
far [28,95]. The vertebrate MMPs each have distinct but
often overlapping substrate specificities. Human MMPs
fall into five classes according to primary structure and
substrate specificity: collagenases, gelatinases, strome-
lysins, membrane-type and nonclassified MMPs [96].
MMPs regulate cell behavior in numerous ways, including
cell-matrix and cell-cell interactions and the release, acti-
vation or inactivation of autocrine or paracrine signaling
molecules and cell surface receptors. ECM-degradation
permits cellular invasion to take place and influence proc-
esses such as cell shape, movement, cytoskeleton machin-
ery and matrix-derived signals [95]. MMPs are regulated at
several levels, including transcriptional, secretion, activa-
tion, inhibition and degradation. Transcriptional regula-
tion is cell, tissue and MMP-specific and includes several
cytokines and growth factors [97]. MMPs are produced as
proenzymes, requiring removal of the propeptide domain
for activation. The extracellular activation of most MMPs
can be initiated by activated MMPs or by several serine
proteinases, including uPA, plasminogen, thrombin and
elastase. MMP-2 is activated at the cell surface through a
multi-step pathway involving membrane type (MT) –
MMPs and TIMP-2 [98]. MMPs are inhibited by α2-mac-
roglobulin, in tissue fluids, and in tissue by TIMPs, which
bind to MMPs in a 1:1 stoichiometric fashion [99].
In vitro studies suggest that successful implantation and
placentation result from the balance between secretion of
MMPs from the trophoblast and their inhibition by TIMPs
[100,101]. The gelatinases, MMP-2 and -9, degrade Colla-Reproductive Biology and Endocrinology 2005, 3:56 http://www.rbej.com/content/3/1/56
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gen IV, the main component of the basement membrane,
and are therefore regarded as key enzymes in the implan-
tation process, enabling the invasion of the trophoblast
cells through the decidua and into the maternal vascula-
ture. Several in vitro studies have found the gelatinases to
be required for trophoblast invasion [102-105,32].
Gelatinases, mainly MMP-2, are secreted from the embryo
already at the blastocyst stage [106-108]. Lately we and
others have shown, that MMP-2 and MMP-9 have a differ-
ential expression throughout the first trimester, with
MMP-2 being the main gelatinase in early first trimester
(6–8 w) and MMP-9 being dominant in late first trimester
(9–12 w) [32,104]. MMPs may have other important
actions in the implantation process, besides ECM degra-
dation, including regulation of bioactivity of growth fac-
tors, cytokines and angiogenic factors [27]. This includes
MMP-2 or -9 activation of TGFβ [109] or release of IGF by
degradation of IGFBPs [110]. Another role may be modu-
lation of angiogenic factors such as endothelin-1, a vaso-
constrictor [111], or angiostatin, an angiogenic inhibitor
[112]. Interestingly, knockout mice, deficient in MMP-2
or MMP-9, are fertile and only mild effects have been
reported: MMP-2 deficient mice have a subtle delay in
their growth [113] and MMP-9 deficient mice show a
decreased litter size and an increase in percentage of infer-
tile mice [114].
MT1-MMP deficient mice die before puberty; therefore no
conclusions can be made on reproductive capacity [115].
In MMP-7 null-mice both MMP-3 and MMP-10 were up-
regulated in the uterus, whereas in MMP-3 deficient mice
MMP-7 and MMP-11 were up-regulated, thereby indicat-
ing the presence of a compensation mechanism [116].
The MMP gene promoter contains several cis-regulatory
elements, often acting synergistically, with varying impor-
tance and effect, depending upon cell-type and inducer.
AP-1 sites give several MMP genes in various cell types the
ability to be induced by phorbol esthers and act in some
cases synergistically with adjacent Ets-binding sites
[117,2,118]. AP-1 was found to be necessary, but not suf-
ficient for transactivation of the MMP-9 gene in human
trophoblasts, and antisense against Jun and Fos transcrip-
tion factors, belonging to the AP-1 complex, was found to
inhibit MMP-9 gelatinolytic activity in trophoblasts [118].
The importance of the Ets site was shown by the study of
knockout mice for ets2 transcription factor, which
resulted in deficient MMP-9 expression and early embry-
onic lethality [119]. Lately, it has been shown that EGF
induction of MMP-9 as well as TIMP-1 in an extravillous
trophoblastic cell-line is through the MAPK and PI3K
pathways [37].
Recently ADAM (a disintegrin and metalloproteinase,
adamalysin)-19 has been detected during early pregnancy
in the endometrium and the placenta of the rhesus mon-
key, and may therefore also be involved in trophoblast
invasion and degradation of the ECM [120].
8.2 TIMPs
Tissue inhibitors of matrix metalloproteinases (TIMPs)
are the main inhibitors of MMPs in tissue, physiologically
controlling their activity. The four known TIMP proteins
(TIMP 1–4) inhibit MMPs in a 1:1 stoichiometric fashion,
by interaction of mainly the C-terminal with the MMP cat-
alytic site. Individual TIMPs differ in their ability to
inhibit various MMPs, and in their gene regulation and
tissue-specific patterns of gene expression [121]. TIMP-1
and 2 exhibit inhibitory activity against the active forms of
all MMPs, TIMP-1 preferentially binding MMP-9 in both
active and latent form [122], and TIMP-2 preferentially
binding active or latent MMP-2 [123]. TIMP-2 in addition
has an important role in activation of MMP-2, together
with MT1-MMP.
TIMPs (1–3) are produced by trophoblastic and decidual
tissues throughout gestation [124,125,100]. TIMP-4 is
secreted from mouse blastocyst, and the addition of spe-
cific TIMP-4 antibody increases the expression and activity
of MMP-2 and MMP-9 [126]. In addition this group also
found TIMP-4 to be expressed in a malignant choriocarci-
noma human cell-line (JEG-3) [127]. Lately TIMP-1 and -
3 and to a lesser extent TIMP-2 were detected in pre-
implantation human embryos, indicating that MMP and
TIMP genes are among the first genes to be expressed in
the developing embryo, preparing for implantation [128].
Growth factors and cytokines known to effect trophoblast
invasiveness may act by up or down-regulation of TIMPs.
TGF-β for example inhibits trophoblast invasion by up-
regulating TIMP-1 and PAI-1 and down-regulating uPA
[129]. TIMPs may have additional roles besides MMP
inhibition, including increasing cell proliferation
[130,131] and embryo development [132].
8.3 Serine proteases
The plasminogen activator system includes the urokinase-
type plasminogen activator (uPA), the tissue-type plas-
minogen activator (tPA), the PA inhibitors PAI-1 and PAI-
2 and the cell surface uPA receptor. The PA system con-
verts plasminogen into the active serine protease plasmin,
which can degrade ECM. The activity of the PA system is
balanced by the inhibitors (PAI-1 and -2) [133]. Besides
directly degrading ECM, the PA system has an indirect
effect, through proteolytic activation of MMPs. Both uPA
and plasmin are reported in the uterus [134] and in tro-
phoblasts [135]. Studies in mice and rats suggest a role for
the PA system in the implantation process [136]. A recent
report found that Adrenomedullin (ADM), a polypeptideReproductive Biology and Endocrinology 2005, 3:56 http://www.rbej.com/content/3/1/56
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belonging to calcitonin gene-related peptide superfamily,
enhances in vitro trophoblast proliferation and invasion
[137]. Both ADM binding sites and ADM are present in
the trophoblasts, the latter is most abundant in first tri-
mester placenta [138]. The report showed that ADM
decreased PAI-1 expression and increased MMP-2 activity,
thereby enhancing the downstream reaction of cell inva-
sion [137].
9. Endovascular invasion
The development of a placental vascular network is essen-
tial for the growth and maintenance of the developing
embryo. Several factors are involved in this angiogenic
process, including VEGF (vascular endothelial growth fac-
tor), PDGF (platelet-derived growth factor) and PAF
(platelet-activating factor) [26].
VEGF induces angiogenesis and increases permeabiliza-
tion of blood vessels. VEGF and its receptors are expressed
in both the endometrium and in trophoblastic cells [1].
Mouse embryos with functional inactivation of one VEGF
allele die on day 11–12 of pregnancy and show several
malfunctions on the vascular system [139]. VEGF mRNA
expression can be detected already in the blastocyst, ena-
bling the implanting embryo to induce angiogenesis at
the implantation site by binding to endometrial receptors
[1]. VEGF expression is up-regulated in placental tissues
by hypoxia, associated with early placental development,
whereas another angiogenic factor PIGF (Placental growth
factor) is down-regulated [140]. Surprisingly placental
VEGF was reduced in pre-eclamptic pregnancies, despite
the prolonged hypoxic condition associated with pre-
eclampsia [141]. PIGF, on the other hand, was decreased
A schematic representation of a blastocyst approaching the receptive endometrium, defined by the integrin profile and appear- ance of pinopodes Figure 1
A schematic representation of a blastocyst approaching the receptive endometrium, defined by the integrin profile and appear-
ance of pinopodes. Early signaling between the blastocyst and the endometrium precedes the attachment.Reproductive Biology and Endocrinology 2005, 3:56 http://www.rbej.com/content/3/1/56
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in pre-eclampsia, as expected [142]. TGF-β and TNF-α,
two pro-angiogenic factors present in the uterus, increased
VEGF expression in a trophoblast cell-line [143]. This is
especially interesting in light of the elevated TGF-β level,
thought to be involved in pre-eclampsia [42], which may
be an attempt to raise the low VEGF level.
ICAM (intercellular adhesion molecule), VCAM (vascular
cell adhesion molecule) and PECAM (platelet endothelial
cell adhesion molecule) are endothelial-cell adhesion
molecules, playing an important role in endothelial acti-
vation and are elevated in the maternal circulation during
pregnancy. Co-culture of endothelial cells and trophob-
lasts lead to an increased expression of ICAM, VCAM and
E-selectin, indicating that factors released from the tro-
phoblasts activate endothelial cells [108]. In pre-eclamp-
tic pregnancies the expression of these adhesion
molecules in the maternal circulation is further increased
[108,144]. Elevated expression of E-selectin, as found in
pre-eclampsia and in placental tissues cultured under
hypoxia-reoxygenation conditions, may be mediated by
the cytokine tumor necrosis factor-alpha, since anti-TNFα
antibody reduced this activation [145]. Elevated VCAM in
maternal blood together with elevated hyperhomo-
cyst(e)inemia, a preeclampsia risk factor, were found to be
strongly associated with an increased risk of preeclampsia
[146]. This is in contrast to the result of an immunocyto-
chemical study of placental bed biopsies from normal and
pre-eclamptic women, which found no difference in
ICAM, PECAM, VCAM and E-selectin expression between
the two groups, suggesting that these molecules are not
implicated in the etiology of pre-eclampsia [147]. In
another study MCAM (melanoma cell adhesion mole-
cule) expression was reduced in trophoblasts in placentas
A schematic representation of an implanting blastocyst, highlighting interactions between trophoblastic and endometrial cells,  including integrins, growth factors, cytokines, hormones and proteases Figure 2
A schematic representation of an implanting blastocyst, highlighting interactions between trophoblastic and endometrial cells, 
including integrins, growth factors, cytokines, hormones and proteases.Reproductive Biology and Endocrinology 2005, 3:56 http://www.rbej.com/content/3/1/56
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from pre-eclamptic women compared to normal, as
detected by immunohistochemistry [148]. VCAM is lower
in term than in first trimester placenta, indicating impor-
tance in the developmental stage. The reduced VCAM
expression found in pregnancies complicated with fetal
growth restriction further supports this concept [149]. In
a comparison study of first trimester serum between nor-
mal pregnant women and women with pregnancy-
induced hypertension (PIH) ICAM and E-selectin, but not
VCAM or P-selectin, were significant higher in women
who developed PIH late in gestation, suggesting that these
factors can serve as effective indicators of the onset of PIH
[150].
10. Conclusion
Ethical restrictions and limited availability of human tis-
sue confined our studies on human implantation. It must
be appreciated that most knowledge comes from in vitro
experiments using cultured human trophoblasts or cell-
lines and in vivo studies from other species. All the same,
it is clear today that the implantation process depends on
appropriate timing and is regulated by various factors of
both maternal and embryonic origin. The success of this
process is a result of complex interactions between these
factors and comprehension of the process demands fur-
ther characterization of these interactions.
New technologies that allow the profiling of tissues at the
genomic, transcriptomic and proteomic levels are becom-
ing available will probably bring more information and
hopefully will help to shed more light on the implanta-
tion process. Further understanding of the process will
enable new strategies in treating implantation failure both
in natural and in assisted reproduction.
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